Abstract 2848
Background
Lysosome has been described as target of interest for cancer therapy. GNS561 is a new lysosomotropic small molecule which displays meaningful activity against several tumor types, specifically in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Herein, we report preliminary results of the Phase 1b/2a study of GNS561 in advanced primary liver cancer patients.
Methods
The Phase 1b portion is a non-randomized, one arm (3 + 3 design) clinical trial with a maximum enrolment of 36 patients. GNS561 was administered orally to histologically confirmed HCC or iCCA adult patients not eligible for curative therapy in 4 week cycles. The objectives are to assess the safety and pharmacokinetics (PK) of GNS561 and to determine the recommended phase 2 dose. Early safety, PD and PK data from patients of the 4 first dose levels are reported.
Results
As of May 2019, 13 patients were enrolled with 10 patients having completed the study with at least one cycle of treatment. Median patient age was 66 years (range 31 - 80), 3 (23%) were female, 6 (46%) had HCC; median number of prior systemic therapies was 1 (range 1-5). Patients received a median number of 2 cycles of GNS561. Six (46%) patients interrupted treatment because of tumor progression, 31% (n = 4) for investigator decision, and 7.7% (n = 1) for serious adverse event. Thus far, no dose limiting toxicity (DLT), or DLT equivalent toxicity have been observed. Most of related-AEs are digestive toxicities (grade 1-2 nausea, vomiting and diarrhea), fatigue and blood parameters abnormalities. The 400 mg cohort is currently ongoing. 70% (n = 7) patients were evaluable for tumor imaging assessment: 43% of them (n = 3) were stable at the beginning of Cycle 3, among which 2 patients had stable disease at the beginning of Cycle 5. Patients showed increasing exposure to GNS561 along with the dose in blood and liver, with dose-proportionality in plasma. Liver concentrations are at least 200 fold higher than in plasma.
Conclusions
Current data show patients that oral GNS561 displays a favorable safety profile, and exposure in blood and liver throughout the dosing interval. Enrollment in Phase 1b is continuing before extension to Phase 2a.
Clinical trial identification
2017-003585-27.
Editorial acknowledgement
Legal entity responsible for the study
Genoscience Pharma.
Funding
Genoscience Pharma.
Disclosure
A.H. Awada: Honoraria (institution), Advisory / Consultancy: Genoscience Pharma. J.J. Harding: Honoraria (institution), Advisory / Consultancy: Genoscience Pharma. N. Kotecki: Honoraria (institution): Genoscience Pharma. P.G. Aftimos: Honoraria (institution): Genoscience Pharma. T. Decaens: Honoraria (institution): Genoscience Pharma. C. Dreyer: Honoraria (institution): Genoscience Pharma. C. Ansaldi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genoscience Pharma. M. Rachid: Full / Part-time employment: Genoscience Pharma. C. Serdjebi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genoscience Pharma. P. Halfon: Leadership role, Shareholder / Stockholder / Stock options, Officer / Board of Directors: Genoscience Pharma. G.K. Abou-Alfa: Honoraria (institution), Advisory / Consultancy: Genoscience Pharma. E. Raymond: Advisory / Consultancy, Shareholder / Stockholder / Stock options, Full / Part-time employment: Genoscience Pharma.
Resources from the same session
2670 - Molecular subtypes of metastatic(met) gastric cancer(GC) (MoTriGastric): new biomarkers closer to the clinics
Presenter: Maria Alsina Maqueda
Session: Poster Display session 2
Resources:
Abstract
3797 - Exploring candidate signal transduction pathways for targeted therapy in esophageal cancer
Presenter: Aafke Creemers
Session: Poster Display session 2
Resources:
Abstract
5485 - Clinical implication of CLDN18, RhoGAP, and E-cadherin in gastric signet ring cell carcinoma
Presenter: Hyunho Kim
Session: Poster Display session 2
Resources:
Abstract
1970 - Identification of a spectrum of germline mutations for hereditary diffuse gastric cancer in the Russian population by next-generation sequencing.
Presenter: IRINA EFIMOVA
Session: Poster Display session 2
Resources:
Abstract
4989 - The molecular profiling and prognostic value of Chinese gastric signet ring cell carcinoma patients
Presenter: Jia Wei
Session: Poster Display session 2
Resources:
Abstract
7145 - A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors
Presenter: Alison Schram
Session: Poster Display session 2
Resources:
Abstract
1406 - Simultaneous Resection of Pancreatic Cancer and Liver Oligometastases After Induction Chemotherapy in Stage IV Patients:an Open-Label Prospective Randomized Multicenter phase 3 trial(CSPAC-1)
Presenter: Miaoyan Wei
Session: Poster Display session 2
Resources:
Abstract
1530 - Multicenter randomized phase II trial of 5-Fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
Presenter: Changhoon Yoo
Session: Poster Display session 2
Resources:
Abstract
1563 - A randomized phase II study of Maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced Pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)
Presenter: Cindy Neuzillet
Session: Poster Display session 2
Resources:
Abstract
2780 - A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Presenter: Do-Youn Oh
Session: Poster Display session 2
Resources:
Abstract